Company news
Carvolix (EURONEXT:CVX) news
Carvolix news releases on 6ix. Latest, Sep 30, 2026: Carvolix Appoints Anne Lange as Chair of its Board of Directors Confirming the Acceleration…
Press releases & updates
Carvolix Appoints Anne Lange as Chair of its Board of Directors Confirming the Acceleration of its Ambitions and Reports 2026 Half-Year Results.
September 30, 2026
Carvolix nomme Anne Lange à la présidence de son Conseil d'administration et publie ses résultats semestriels 2026, confirmant l'accélération de ses ambitions.
September 29, 2026
Carvolix Appoints Anne Lange as Chair of its Board of Directors Confirming the Acceleration of its Ambitions and Reports 2026 Half-Year Results.
September 29, 2026
Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
September 22, 2026
Carvolix Takes a Key Step Toward Commercial Launch of TAVIPILOT Software in Europe with Regulatory Submission for CE Marking.
September 9, 2026
Carvolix Secures EUR 30 Million Of Structured Debt Financing To Fuel Its Growth.
August 6, 2026
Carvolix : ODDO BHF initiates coverage of Carvolix with an Outperform rating.
July 29, 2026
Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
July 6, 2026
Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
June 24, 2026
Carvolix announces positive 3-years clinical results for Kalios™ , the only adjustable mitral ring. 100% of patients met primary endpoint for mitral regurgitation.
June 15, 2026
Carvolix Announces Positive Results of the Postmarketing Clinical Program Evaluating the TAVIPILOT AI Software.
May 4, 2026
Carvolix Strengthens its Board of Directors, and International Advisory Bodies
April 9, 2026
Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile.
March 23, 2026
Carvolix : Estimated full-year 2025 results.
March 19, 2026
Carvolix : Results of the votes of the Combined Shareholders’ General Meeting of January 30, 2026
February 2, 2026
Affluent Medical officially becomes CARVOLIX
February 2, 2026
Affluent Medical announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies.
December 19, 2025